Variable | Non-VT group (n = 48) | VT group (n = 22) | P |
---|---|---|---|
Gender (male) | 31 (64.5Â %) | 15 (68.2Â %) | 0.77 |
Age (years) | 61.2 ± 11.4 | 60.6 ± 11.8 | 0.86 |
BUN (mmol/L) | 6.0 ± 1.5 | 6.1 ± 1.2 | 0.84 |
Cr (μmol/L) | 76.3 ± 15.8 | 77.1 ± 15.2 | 0.82 |
FBG (mmol/L) | 5.0 ± 0.9 | 5.1 ± 0.8 | 0.79 |
TC (mmol/L) | 4.8 ± 0.6 | 4.7 ± 0.7 | 0.83 |
LVEF (%) | 59.8 ± 6.4 | 58.7 ± 6.5 | 0.87 |
β2 agonist use | 45 (93.8 %) | 20 (90.9 %) | 1.00 |
Anticholinergic use | 40 (83.3Â %) | 19 (86.4Â %) | 1.00 |
Hormone replacement therapy | 36 (75.0Â %) | 17 (77.3Â %) | 0.84 |
Calcium antagonist use | 15 (31.2Â %) | 10 (45.5Â %) | 0.25 |
Amiodarone use | 5 (10.4Â %) | 15 (68.2Â %) | <0.05 |
Smoker | 10 (20.8Â %) | 6 (27.3Â %) | 0.64 |
PH | 7.40 ± 0.05 | 7.41 ± 0.08 | 0.13 |
PaO2(mmHg) | 60.5 ± 5.9 | 59.8 ± 5.3 | 0.73 |
PaCO2(mmHg) | 49.4 ± 5.6 | 50.5 ± 5.9 | 0.43 |
Serum K+(mmol/L) | 4.2 ± 0.4 | 4.1 ± 0.4 | 0.25 |
Serum Na + (mmol/L) | 138.8 ± 3.3 | 139.7 ± 3.2 | 0.12 |
Serum Cl-(mmol/L) | 99.8 ± 2.0 | 98.8 ± 2.2 | 0.06 |
mMRC Grade 0 | 10 (20.8Â %) | 5 (22.7Â %) | 0.88 |
mMRC Grade 1 | 15 (31.2Â %) | 6 (27.3Â %) | 0.80 |
mMRC Grade 2 | 12 (25Â %) | 5 (22.7Â %) | 0.87 |
mMRC Grade 3 | 8 (16.7Â %) | 4 (18.2Â %) | 0.89 |
mMRC Grade 4 | 3 (6.3Â %) | 2 (9.1Â %) | 0.69 |